Bibliography
- GATTONE VH 2nd, WANG X, HARRIS PC, TORRES VE: Inhibition of renal cystic disease development and progression by a vasopressin V2 receptor antagonist. Nat. Med. (2003) 9:1323–1326.
- WILSON PD: Polycystic kidney disease. N Engl. J. Med. (2004) 350:151–164.
- PROMENEUR D, KWON T-H, FROKLER J, KNEPPER MA, NIELSEN S: Vasopressin V2-receptor-dependent regulation of AQP2 expression in Brattleboro rats. Am. Physiol Renal Physic] (2000) 279:F370–F382.
- YAMAGUCHI T, PELLING JC, RAMASWAMY NT et al.: cAMP stimulates the M vitro proliferation of renal cyst epithelial cells by activating the extracellular signal-regulated kinase pathway. Kidney Int. (2000) 57:1460–1471.
- HANAOKA K, GUGGINO W: cAMP regulates cell proliferation and cyst formation in autosomal polycystic kidney disease cells. J. Am. Soc. Nephrol (2000) 11:1179–1187.
- YAMAMURA Y, OGAWA H, YAMASHITA H et al.: Characterization of a novel aquaretic agent, OPC-31260, as an orally effective, nonpeptide vasopressin V2 receptor antagonist. Br. J. Pharmacol (1992) 105:787–791.
- OHNISHI A, ORITA V, TAKAGI N et al.:Aquaretic effect of a potent, orally active, nonpeptide V2 antagonist in men. Pharmacol Exp. Ther. (1995) 272:546–551.
- WARD CJ, HOGAN MC, ROSSETTI S et al.: The gene mutated in autosomal recessive polycystic kidney disease encodes a large, receptor-like protein. Nat. Genet. (2002) 30:259–269.
- OLBRICH H, FLIEGAUF M, HOEFELE J et al: Mutations in a novel gene, NPHP3, cause adolescent nephronophthisis, tapeto-retinal degeneration and hepatic fibrosis. Nat. Genet. (2003) 34:455–439.
- BOSCH-MARCE M, POO J-L, JIMENEZ W et al: Comparison of two aquaretic drugs (niravoline and OPC-31260) in cirrhotic rats with ascites and water retention. Pharmacol Exp. Ther. (1999) 289:194–201.
- JIMENEZ W, SERRADEIL-LE GAL C, ROS J et al.: Long-term aquaretic safety of a selective nonpeptide V2 receptor antagonist, 5R121463, in cirrhotic rats. Pharmacol Exp. Ther. (2000) 295:83–90.
- GUYADER D, PATAT A, ELLIS-GROSSE EJ, ORCZYK GP: Pharmacodynamic effects of a nonpeptide V2 antagonist in cirrhotic patients with ascites. Hepatology (2002) 36:1197–1205.
- WONG F, BLEI AT, BLENDIS LM, THYLUVATH PJ: A vasopressin receptor antagonist (VPA-985) improves serum sodium concentration in patients with hyponatremia: a multicenter, randomized, placebo-controlled trial. Hepatology (2003) 37:182–191.
- GERBES AL, GULBERG V, GINES P et al.: Therapy of hyponatremia in cirrhosis with a vasopressin receptor antagonist: a randomized double-blind multicenter trial. Gastroenterology (2003) 124:933–939.
- YAMAMURA Y, NAKAMURA S, ITOH S et al: OPC-41061, a highly potent vasopressin V2-receptor antagonist: pharmacological profile and aquaretic effect by single and multiple oral dosing in rats. Pharmacol Exp. The]: (1998) 287:860–867.
- GHEORGHIADE M, NIAZI I, OUYANG J et al.: Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure: results from a double-blind, randomized trial. Circulation (2003) 107:2690–2696.